NICE has recommended regular NHS funding for Takeda’s Adcetris in an aggressive type of non-Hodgkin lymphoma after the company submitted further data to support its case.
AstraZeneca could receive up to $400 million from Takeda after approaching the company to jointly develop and market a new treatment for Parkinson’s disease (PD).
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
